ONCS -54% on SITC-related PR and CC: https://finance.yahoo.com/news/oncosec-reports-preliminary-data-keynote-130000623.html ONCS’ TAVO + Keytruda had ORR=22% (2/9) in second-line Stage-II/IV melanoma (following PD-1 monotherapy in the first line). Holding a CC to tout these interim data was probably a bad idea.